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Apelin decreases myocardial injury and improves right ventricular function
in monocrotaline-induced pulmonary hypertension
Ineˆs Falca˜o-Pires, Na´dia Gonc¸alves, Tiago Henriques-Coelho, Daniel Moreira-Gonc¸alves,
Roberto Roncon-Albuquerque Jr., and Adelino F. Leite-Moreira
Department of Physiology, Cardiovascular R and D Unit, Faculty of Medicine, University of Porto, Porto, Portugal
Falca˜o-Pires I, Gonc¸alves N, Henriques-Coelho T, Moreira-
Gonc¸alves D, Roncon-Albuquerque R Jr, Leite-Moreira AF. Ape-
lin decreases myocardial injury and improves right ventricular func-
tion in monocrotaline-induced pulmonary hypertension. Am J Physiol
Heart Circ Physiol 296: H2007–H2014, 2009. First published April 3,
2009; doi:10.1152/ajpheart.00089.2009.—We investigated the endog-
enous production of apelin and the cardiac and pulmonary effects of
its chronic administration in monocrotaline (MCT)-induced pulmo-
nary hypertension (PH). Male Wistar rats were injected with MCT (60
mg/kg sc) or vehicle (day 0). One week later, these animals were
randomly treated during 17 days with pyroglutamylated apelin-13
(Pyr-AP13; 200 g kg1 day1 ip) or a similar volume of saline,
resulting in four groups: sham (n  11), sham-AP (n  11), MCT
(n  16), and MCT-AP (n  13). On day 25, right ventricular (RV)
and left ventricular (LV) hemodynamic and morphometric parameters
were assessed. Tissue and plasma samples were collected for histol-
ogical and molecular analysis. When compared with sham, the MCT
group presented a significant increase of RV mass (166  38%),
diameter of cardiomyocyte (40  10%), myocardial fibrosis (95 
20%), peak systolic pressure (99  22%), peak rate of ventricular
pressure rise (dP/dtmax; 74  24%), peak rate of ventricular pressure
decline (dP/dtmin; 73  19%), and time constant  (55  16%). In
these animals, RV expression of apelin (73  10%) and its receptor
APJ (61 20%) was downregulated, whereas mRNA expression of
type B natriuretic peptide (9,606  713%), angiotensinogen (191 
147%), endothelin-1 (RV, 497  156%; and LV, 799  309%),
plasmatic levels of apelin (104  48%), and angiotensin 1-7 (161 
151%) were increased. Chronic treatment with Pyr-AP13 significantly
attenuated or normalized these changes, preventing apelin-APJ
mRNA downregulation and PH-induced neurohumoral activation of
several vasoconstrictors, which exacerbates apelin-APJ vasodilator
effects. Therefore, apelin delayed the progression of RV hypertrophy
and diastolic dysfunction. Together, these observations suggest that
the apelin-APJ system may play an important role in the pathophys-
iology of PH, representing a potential therapeutic target since it
significantly attenuates RV overload and PH-induced neurohumoral
activation.
heart failure; angiotensin receptor like-1; right ventricle hypertrophy
ANGIOTENSIN RECEPTOR like-1 (APJ) and its endogenous ligand,
apelin, represent a recently discovered system that regulates
cardiac function (38). Both are distributed in the heart, lungs,
central nervous system, and gastrointestinal tract. In the car-
diovascular system, APJ is located in cardiomyocytes and
vascular smooth muscle cells, whereas apelin is produced in
endocardial endothelial cells, prompting the suggestion that
endothelial apelin may act as a paracrine mediator of APJ
receptor to influence cardiac contractility or vascular tone (23,
25). Little is known about the regulation of apelin production
in cardiovascular tissues; however, angiotensin converting en-
zyme-2 (ACE2), a zinc metalloproteinase that catalyzes the
conversion of angiotensin II (ANG II) to angiotensin-(1–7)
[ANG-(1–7)], has been identified as the only enzyme that
breaks down apelin peptides (41).
The intense research on apelin has shown its involvement in
the regulation of cardiovascular function (3, 10, 35), hemody-
namic homeostasis (6), immune response (18), brain signaling
(11, 30), and HIV infection (5), as well as insulin secretion in
mice (34). Particularly, in the cardiovascular system, the ape-
lin-APJ system has been the focus of several studies, including
the human heart (7), but its physiological role is not yet
completely understood. Apelin-APJ vascular effects are con-
troversial, although suggesting that they may depend on endo-
thelial integrity, i.e., vasodilator through endothelial-dependent
nitric oxide (NO) release (8, 39), or vasoconstrictor, in the
presence of a dysfunctional endothelium, by direct binding to
APJ in vascular smooth muscle cells (22). In isolated rat hearts,
apelin acts as one of the most potent positive inotropic sub-
stances identified to date, both in normal (1, 3, 10, 35) and in
heart failure (3, 10, 12) rats, including right ventricular (RV)
failure secondary to hypoxia-induced pulmonary hypertension
(PH). In normal hearts, these effects depend on phospholipase
C, protein kinase C, Na-H exchanger, and Na-Ca2 ex-
changer (36) activation, whereas in the failing RV due to PH it
is dependent of increased calcium transients, rather than of
changes in myofilament calcium responsiveness (10).
PH is a progressive disease associated with RV hypertrophy
that commonly progresses to heart failure. Endothelin (ET)-1
and several other neurohumoral agents notably worsen the
complex pathophysiology of PH (16, 32), and its antagonists
are used as therapeutic targets for this entity. So far, the effects
of apelin in PH have never been studied, even if its unusual
combination of positive inotropic and afterload reduction ef-
fects suggests that the apelin-APJ pathway may represent a
potential therapeutic target in PH. Furthermore, considering
that apelin-APJ are abundant in heart and lungs and that its
localization might provide a clue to its physiological role, we
investigated whether exogenous pyroglutamylated apelin-13
(Pyr-AP13) could chronically change the pathophysiological
progression of PH as well as RV functional performance.
Therefore, the aim of the present study was to better under-
stand the physiological role of the apelin-APJ system in PH
and to elucidate the effects of its exogenous administration in
biventricular function, pulmonary and RV structure, and neu-
rohumoral activation as well as apelin and APJ expression and
production in healthy and monocrotaline (MCT)-PH rats.
MATERIAL AND METHODS
Experimental design. Animal experiments were performed accord-
ing to the Portuguese law for animal welfare and accordingly to the
Guide for the Care and Use of Laboratory Animals published by the
National Institutes of Health (NIH Publication No. 85-23, Revised
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1996). The Faculty of Medicine at the University of Porto is a
governmental institution granted approval by the Portuguese govern-
ment to perform animal experiments as described in this study. Adult
male Wistar rats (Charles River Laboratories, Barcelona, Spain)
weighing 160–180 g were housed in groups of five rats per cage in a
controlled environment under a 12-h:12-h light-dark cycle at a room
temperature of 22°C, with a free supply of food and water.
Rats randomly received a subcutaneous injection of MCT (n  29;
60 mg/kg body wt; Sigma, Barcelona, Spain) or an equal volume of
vehicle (n  22; 2 ml/kg body wt). One week after MCT/vehicle
injection (day 0), 13 random MCT animals and 11 random vehicle
animals received an intraperitoneal injection of Pyr-AP13 (200
g kg1 day1; Bachem, Weil and Rhein), whereas the remaining
rats received equal volume of saline until day 24, one day before
hemodynamic assessments. This chronic protocol resulted in four
groups: control rats treated with saline (sham; n  11) or Pyr-AP13
(sham-AP; n  11) and MCT-treated rats with saline (MCT; n  16)
or Pyr-AP13 (MCT-AP; n  13). The physiologically active form is
apelin-36, but the most biologically effective are apelin-16 and the
pyroglutamylated form of apelin-13. This common posttranslational
modification preserves biological activity by rendering the peptide
more resistant to enzymatic cleavage. Therefore, we used Pyr-AP13
for this chronic study. The peptide was dissolved in distilled, auto-
claved water and frozen at 20°C.
Hemodynamic studies. Twenty-five days after MCT/vehicle injec-
tion, the rats were anesthetized by inhalation of a mixture of sevoflu-
rane (4%) and oxygen, intubated for mechanical ventilation, and
placed over a heating pad. Under binocular surgical microscopy (Wild
M651.MS-D; Leica), the right jugular vein was cannulated for fluid
administration (prewarmed 0.9% NaCl solution) to compensate for
perioperative losses. The heart was exposed through a median ster-
notomy, and the pericardium was widely opened. RV and left ven-
tricular (LV) pressures were measured with a 2F high-fidelity micro-
manometer (SPR-324; Millar Instruments) inserted into the RV and
LV cavities, respectively. After complete instrumentation, the animal
preparation was allowed to stabilize for 15 min. Hemodynamic
recordings were made with respiration suspended at end expiration.
Parameters were converted online to digital data with a sampling
frequency of 1,000 Hz. RV and LV pressures were measured at end
diastole and peak systole (Pmax). Peak rates of RV and LV pressure
rise (dP/dtmax) and pressure decline (dP/dtmin) were measured as well.
The relaxation rate was estimated with the time constant  by fitting
the isovolumetric pressure fall to a monoexponential function. At the
end of the experimental protocol, a blood sample (2 to 3 ml) was
collected using a syringe with heparin for plasmatic quantification of
apelin and ANG-(1–7).
Morphometric analysis and tissue preparation. Once hemody-
namic data collection was completed, the heart, lungs, and right
gastrocnemius muscle were excised and weighed. The right tibia was
also excised and measured using a millimetric ruler. Under binocular
magnification (3.5), the RV free wall was dissected from the LV and
weighed separately. Heart, lung, RV, and LV  septal (LV  S)
weights were normalized to body weight (BW), whereas gastrocne-
mius weight was normalized to tibial length. Additionally, RV weight
was normalized to that of LV  S.
Histology. RV and right lung samples were immersion fixed in 10%
buffered formalin and embedded in paraffin. Sections 4 m thick were
cut and stained with hematoxylin and eosin. RV free wall specimens
were obtained from each heart at midway between the apex and base.
Studied samples were photographed with a digital camera, and the
cardiomyocyte diameter was measured, in each section, using a digital
image analyzer (Leica IM-1000). These measurements were made
directly at 400 magnification only in muscle fibers in which the
cross section included a round nucleus. Five sections per sample were
photographed, and the diameter of 10 muscle fibers was measured.
The diameter of 50 analyzed cardiomyocytes per sample was then
averaged. Subsequent image analysis with Slidebook 4.0 software (3I)
was performed to determine the extent of myocardial reactive inter-
stitial fibrosis (percentage). Areas of reparative and perivascular
fibrosis were excluded.
Pulmonary specimens of each animal were collected from the
upper right lobe. External diameter and medial wall thickness in
muscular arteries (12 arteries/lung) were analyzed at 400 magnifi-
cation. Orthogonal intercepts generated eight random measurements
of external diameter of the vessels (distance between the external
lamina) and 16 random measurements of medial thickness of the
vessels (distance between the internal and external lamina). For each
artery, medial hypertrophy was expressed as follows: %wall thick-
ness  [(medial thickness  2)/(external diameter)]  100.
Plasma analysis. Venous blood samples collected in ethylenedia-
mine-tetra-acetic acid-containing tubes were spun at 5,000 rpm for 15
min at 4°C, and plasma was extracted and frozen at 70°C until
analysis. Apelin assays were performed using the apelin-36 micro-
plate ELISA assay kit (Phoenix Pharmaceuticals, Karlsruhe, Ger-
many) according to the manufacturer’s instructions. The antibody
used in this apelin assay cross reacts 100% with rat apelin-36, which
is known to be the precursor of all biologically active peptides of
apelin. Additionally, to indirectly assess ACE2 activity, we measured
the formation of its breakdown product, ANG-(1–7), in plasma
samples. ANG-(1–7) assays were performed using a 96-microplate
ELISA assay kit (Peninsula Laboratory, San Carlos, CA) according to
the manufacturer’s instructions. All plasma samples were analyzed in
duplicate using an ELISA plate reader (Perkin-Elmer, Wellesley,
MA). Values were normalized to a standard curve.
mRNA quantification. Two-step real-time RT-PCR was performed as
previously described (31). Briefly, after total mRNA extraction (no.
74124; Qiagen), standard curves were obtained for each gene correlating
(R  0.98) the mRNA quantities in graded dilutions from a randomly
selected tissue sample with the respective threshold cycles (second
derivative maximum method). Equal amounts of mRNA from every
sample underwent two-step real-time RT-PCR experiments for each
gene, using SYBR green as marker (no. 204143; Qiagen). GAPDH was
used as internal control because its mRNA levels were similar in the
studied groups. Results are relative to the mean obtained for the sham
group (set as arbitrary unit) and normalized for GAPDH. Specific PCR
primer pairs for the studied genes were: GAPDH, forward 5	-
TGGCCTTCCGTGTTCCTACCC-3	 and reverse 5	-CCGCCTGCT-
TCACCACCTTCT-3	; APJ, forward 5	-CCAGTCTGAATGTGAC-
TACGC-3	 and reverse 5	-ACCACAAAGGTC AAGTCAGCC-3	; ape-
lin, forward 5	-TTGACTGCCGTGTGTGGAGTGCCA-3	 and reverse
5	-AAAGGCATGGGTCCCTTATGG- 3	; type B natriuretic peptide
(BNP), forward 5	-GGACCAAGGCCCTACAAAAGA-3	 and reverse
5	-CAGAGCTGGGGAAAGAAGAG-3	; ET-1, forward 5	-CCATG-
CAGAAAGGCGTAAAAG-3	 and reverse 5	-CGGGGCTCTGTAGT-
CAATGTG-3	; angiotensinogen, forward 5	-CGGACAGCAC-
CCTATTTTTCAACA-3	 and reverse 5	- GAGGCGCACTGGGGCT-
GGAT-3	; Mas receptor, forward 5	-CCATCCTCAGCTTCTTGGTC-3	
and reverse 5	-GCATGGCAAAGATGAGGAAT-3	.
Statistical analysis. Statistical analysis was performed using Prim
(version 5.0). Group data are presented as means  SD and were
compared using two-way ANOVA. When the normality test failed,
the two-way ANOVA was preceded by a logarithmic transform to
obtain a normal distribution. When treatments were significantly
different, the Student-Newman-Keuls test was selected to perform
pairwise multiple comparisons. Mortality rates were compared with
Fisher exact test. Corelations between two continuous variables were
assessed with linear regression analysis. Statistical significance was
set at P 
 0.05.
RESULTS
Somatic and cardiac growth. Data related to somatic and
cardiac growth are summarized in Table 1. In the MCT group,
RV, heart, and lung/BW were significantly increased. Treat-
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ment with Pyr-AP13 attenuated the effects of MCT on RV and
lung/BW, whereas no changes were observed in the sham-AP
group. Interaction analysis revealed that effects of Pyr-AP13
on RV and lung/BW were significantly different in sham and
MCT rats. The BW of MCT and MCT-AP rats was similar, but
both were significantly lower than sham and sham-AP animals.
Twenty-five days after injection, the mortality was null in
sham and sham-AP, 33% in MCT and 23% in MCT-AP
groups. Although there was a trend for reduction in mortality
rate in apelin-treated MCT rats compared with MCT, it did not
reach statistical significance.
Hemodynamic assessment. We administrated Pyr-AP13 over
the course of 17 days at a level previously shown to exert acute
and chronic hemodynamic effects (21). Chronic administration
of apelin significantly changed several hemodynamic parame-
ters, especially those related to RV function (Table 2). Peak
systolic RV pressure (RV Pmax), which was used to estimate
PH, RV dP/dtmax, dP/dtmin, and  were significantly increased
in the MCT group. Chronic treatment with Pyr-AP13 markedly
attenuated this effect as observed in the MCT-AP group. No
differences of RV hemodynamics between sham and sham-AP
were observed. Therefore, the effects of Pyr-AP13 on RV
hemodynamics were significantly different in sham and MCT
animals, as confirmed by interaction analysis (Table 2).
Regarding the LV, although there was a tendency for the
MCT group to present a smaller LV Pmax, dP/dtmax, and
dP/dtmin than sham animals, at this stage, no significant differ-
ences were observed, except an increase in . The effects of
apelin on the LV were mostly observed on diastolic function as
confirmed by the decrease of end-diastolic pressure (Table 2).
Morphometric analysis. RV chronic pressure overload sec-
ondary to PH resulted in RV hypertrophy as expressed by
RV/LV  S and RV-to-BW ratios in MCT animals (Table 1).
This RV mass gain was significantly prevented after Pyr-AP13
chronic treatment. Similarly, at the cellular level, the MCT
group presented larger cardiomyocytes than sham animals.
Chronic infusion of Pyr-AP13 significantly reduced cardiomy-
ocyte hypertrophy in the MCT-AP group but did not alter the
size of the cardiomyocyte in sham animals (Fig. 1A). Further-
more, collagen deposition was significantly increased in the
MCT group, a change that was corrected by chronic adminis-
tration of Pyr-AP13 as MCT-AP fibrosis values became com-
parable with those of the sham  AP group (Fig. 1B).
At the pulmonary level, PH significantly induced hypertro-
phy of the pulmonary vessels media in the MCT group, but this
hypertrophy was not prevented by chronic administration of
Pyr-AP13 (Fig. 2). In sham animals, apelin had no effect on
mean vessel wall thickness.
Apelin and ANG-(1–7) plasmatic levels. Apelin-36 and
ANG-(1–7) plasmatic levels were significantly increased in
MCT animals (apelin, 0.77  0.18 vs. 0.38  0.13 ng/ml in
sham, P 
 0.001; and ANG-(1–7), 3.00  1.7 vs. 1.15  0.70
ng/ml in sham, P 
 0.01). Pyr-AP13 chronic administration
normalized apelin-36 and ANG-(1–7) plasmatic levels as ob-
served in the MCT-AP group (0.44  0.15 ng/ml, P 
 0.001
vs. MCT; and ANG-(1–7), 0.99  0.38 ng/ml in MCT-AP,
Table 1. Effect of chronic administration of 17-day apelin on somatic and cardiac growth
Sham Sham-AP MCT MCT-AP
n 11 11 12 10
Body weight, g 32235 32434 27324*† 28327*†
Heart weight/body weight, g/kg 2.870.35 2.980.23 4.200.24*† 3.960.27*†
RV weight/body weight, g/kg 0.470.04 0.510.07 1.250.18*† 0.840.40*†‡§
RV/LV  S, g/g 0.240.02 0.250.04 0.520.05*† 0.410.18*†‡
Lung weight/body weight, g/kg 4.050.55 4.401.13 8.661.95*† 6.371.03*†‡§
Gastrocnemius weight/tibial length, mg/mm 47.97.0 50.33.6 43.84.4 43.04.4
Values are means  SD; n, number in each group. RV, right ventricle; LV  S, left ventricle and septum; AP, apelin; MCT, monocrotaline-treated rats.
Comparisons were performed using two-way ANOVA followed by the Student-Newman-Keuls test to perform pairwise multiple comparisons. *P 
 0.05 vs.
Sham; †P 
 0.05 vs. Sham-AP; ‡P 
 0.05 vs. MCT; §significant interaction.
Table 2. Chronic effects of apelin administration on hemodynamic parameters
Sham Sham-AP MCT MCT-AP
Right Ventricle
Pmax, mmHg 23.15.0 22.84.1 46.94.4*† 32.06.3*†‡§
EDP, mmHg 1.61.5 1.32.1 2.12.0 1.00.8
dP/dtmax, mmHg/s 899193 867149 1,632259*† 1,087311‡§
dP/dtmin, mmHg/s 807156 759115 1,456234*† 984278†‡§
t, ms 12.62.8 13.22.9 19.03.9*† 15.72.5‡§
Left Ventricle
Pmax, mmHg 88.220.6 87.929.8 75.58.4 73.022.7
EDP, mmHg 3.41.6 2.12.1 2.82.0 1.40.7
dP/dtmax, mmHg/s 4,0811,069 4,0091,441 3,8541,720 3,6251,404
dP/dtmin, mmHg/s 3,2851,172 3,3931,337 2,5571,428 2,667749
, ms 13.70.9 12.11.5 17.43.4*† 15.21.8†‡
Values are means  SD. Pmax, peak systolic pressure; EDP, end-diastolic pressure; dP/dtmax, peak rate of ventricular pressure rise; dP/dtmin, peak rate of
ventricular pressure decline; , time constant of isovolumetric relaxation. Comparisons were performed using two-way ANOVA followed by the Student-
Newman-Keuls test to perform pairwise multiple comparisons. *P 
 0.05 vs. Sham; †P 
 0.05 vs. Sham-AP; ‡P 
 0.05 vs. MCT; §significant interaction.
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P 
 0.05 vs. MCT). In sham animals, no significant changes
were observed after treatment with Pyr-AP13 (apelin, 0.36 
0.12 ng/ml, P 0.76; and ANG-(1–7), 1.15 0.78 ng/ml, P
0.46).
Gene expression profile. RV expression of apelin and APJ
was significantly decreased in the MCT animals, revealing a
marked myocardial downregulation of this system in PH.
Pyr-AP13 administration blunted this decrease. Interestingly,
in sham-AP animals, exogenous apelin increased its endoge-
nous myocardial expression (Fig. 3). Regarding the expression
of genes typically involved in autocrine/paracrine activation
during the progression of PH, ET-1, and ANG II, herein
represented by its precursor angiotensinogen, showed an up-
regulation in the MCT group that was prevented by chronic
administration of Pyr-AP13. Surprisingly, Pyr-AP13 treatment
significantly increased the expression of Mas receptor either in
sham or in MCT animals (Fig. 4). As expected from the
myocardial hypertrophy data, the MCT group presented
mRNA overexpression of BNP and Pyr-AP13 chronic admin-
istration remarkably reduced BNP mRNA levels in MCT-AP
(Fig. 5). Interestingly, Pyr-AP13 chronic treatment decreased
ET-1 in the nonoverloaded left ventricle (Fig. 6).
In pulmonary parenchyma of MCT-treated animals, apelin and
APJ showed the same expression trends as in the RV; this is a
decrease in the MCT group and an increase in the MCT-AP
group. However, these differences did not reach statistical signif-
icance. In sham animals, the treatment with Pyr-AP13 did not
change the expression of apelin. No differences between groups
were observed in pulmonary ET-1 mRNA expression (Table 3).
DISCUSSION
In the present study we documented the myocardial beneficial
effects of apelin in MCT-induced pulmonary hypertension. The
most relevant findings were that Pyr-AP13 treatment decreased
PH, RV overload, hypertrophy, and myocardial neurohumoral
activation, improved biventricular diastolic function, and normal-
ized RV mRNA expression of apelin, APJ receptor, and BNP.
Remarkably, exogenous Pyr-AP13 induced its endogenous myo-
cardial expression both in healthy and in PH animals. Moreover,
we demonstrated that apelin ameliorates PH progression not only
by its well-known vasodilator effects but also by its direct mod-
ulation of myocardial neurohumoral activation. These findings
extend and complement previously described cardiovascular ef-
fects of apelin in HF, suggesting an important cardiovascular role
for the apelin-APJ system, namely as a powerful autocrine/
paracrine myocardial modulator in PH.
Previous studies highlighted the importance of the apelin-
APJ system in cardiac overload, reporting that chronic treat-
ment with apelin resulted in increased dP/dtmax, dP/dtmin, and
decreased LV end-diastolic pressure in a HF rat model induced
by isoproterenol (21, 24, 35), whereas in healthy rats, it
Fig. 1. Cardiomyocyte diameter (A) and myocardial fibrosis (percentage; B) in
sham and moncrotaline (MCT) animals treated with saline or apelin [pyroglu-
tamylated apelin-13 (Pyr-AP13)]. Data are means  SD. *P 
 0.05 vs. sham;
†P 
 0.05 vs. sham-AP; ‡P 
 0.05 vs. MCT.
Fig. 2. Mean vessel wall thickness of peripheral pulmonary arteries (25–50
m) in sham and MCT animals treated with saline or apelin (Pyr-AP13). Data
are means  SD. *P 
 0.05 vs. sham; †P 
 0.05 vs. sham-AP.
Fig. 3. Expression of apelin (A) and apelin receptor (APJ; B) in the right
ventricle (RV). Results are normalized for GAPDH and presented in arbitrary
units (AU). Data are means  SD. *P 
 0.05 vs. sham; †P 
 0.05 vs.
sham-AP; ‡P 
 0.05 vs. MCT; §significant interaction.
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induced a significant increase on the velocity of circumferential
shortening and cardiac output without signs of cellular hyper-
trophy (1). Furthermore, apelin knockout mice exhibited nor-
mal cardiac development in adulthood, which deteriorated with
aging or with chronic pressure overload. Interestingly, a con-
tinuous 2-wk infusion of apelin-13 in these elderly mice
reversed the decreased contractility due to aging (24). Partic-
ularly, in a rat model of HF with hypoxia-induced PH, acute
apelin administration in papillary muscles induced a positive
inotropic effect that was greater in HF rats than in healthy rats,
which was attributed to changes in increased intracellular
calcium transients rather than changes in myofilament calcium
responsiveness (10). Our results further strengthen and extend
these previous observations by showing, for the first time, the
beneficial cardiac effects of apelin under increased RV after-
load conditions.
A unique characteristic of apelin, when compared with other
known inotropic agents (2, 4), is the fact that it enhanced RV
function while decreasing myocardial hypertrophy in PH ani-
mals. Even in sham animals it did not promote myocardial
hypertrophy, reinforcing the previous finding of Ashley et al.
(1) that demonstrated that apelin has the capacity to reduce LV
preload and afterload and chronically increase cardiac output
without inducing hypertrophy. Another interesting feature of
this agent relates to its effect on the extracellular matrix: apelin
normalized myocardial fibrosis in the MCT-AP group to values
similar to those of the sham group, which is in consonance with
a previous study that demonstrated an upregulation of collagen
IV mRNA and other sets of genes involved in myocardial
fibrosis in an apelin knockout mice (24).
Contrasting with the important vasodilator effects previ-
ously described in vasculature (8, 20, 39), Pyr-AP13 failed to
prevent pulmonary structural damages induced by MCT ad-
ministration, namely, to attenuate the hypertrophy of the media
in small peripheral pulmonary arteries. However, prognosis
and survival in PH has been related predominantly with the
integrity of RV function rather than with the degree of pulmo-
nary vasculature injury (29).
In the present study, MCT animals showed a significant
reduction of apelin and APJ receptor mRNA expression in the
RV. Our findings are supported by previous observations in
Fig. 4. Expression of endothelin-1 (ET-1; A), angiotensin II (ANG II; B), and
Mas receptor (Mas; C) in the RV. Results are normalized for GAPDH and
presented in arbitrary units (AU). Data are means  SD. *P 
 0.05 vs. sham;
†P 
 0.05 vs. sham-AP; ‡P 
 0.05 vs. MCT; §significant interaction.
Fig. 5. Expression of type B natriuretic peptide (BNP) in the RV. Results are
normalized for GAPDH and presented in arbitrary units (AU). Data are means 
SD. *P 
 0.05 vs. sham; †P 
 0.05 vs. sham-AP; ‡P 
 0.05 vs. MCT.
Fig. 6. Expression of ET-1 in the left ventricle (LV). Results are normalized
for GAPDH and presented in arbitrary units (AU). Data are means SD. *P

0.05 vs. sham; †P 
 0.05 vs. sham-AP; ‡P 
 0.05 vs. MCT.
Table 3. Pulmonary gene expression profile
Sham Sham-AP MCT MCT-AP
Apelin/GAPDH mRNA, AU 1.000.74 1.080.85 0.460.34 1.631.68
APJ/GAPDH mRNA, AU 1.000.86 0.960.69 0.200.12 0.820.53
ET-1/GAPDH mRNA, AU 1.001.20 1.121.06 0.190.11 0.470.50
Values are means  SD. ET-1, endothelin-1; APJ, apelin receptor. Results
are normalized for GAPDH and presented in arbitrary units (AU).
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cultured neonatal rat ventricular myocytes subjected to me-
chanical stretch (35) and also in in vivo models of chronic RV
(10) and LV (42) pressure overload. Remarkably, chronic
exogenous administration of Pyr-AP13 induced an increase in
the endogenous myocardial expression of apelin and Mas
receptor both in healthy and in PH animals although the exact
mechanisms remain to be clarified. In our study, we can
speculate that the increased production of plasmatic apelin-36
in the MCT-treated rats might represent a compensatory re-
sponse to overcome the downregulation of the apelinergic
system in the injured RV. Previous studies have reported
contradictory findings regarding the circulating levels of apelin
in patients with HF [elevated (7), decreased (9, 14, 17), or
unchanged (27)], suggesting its potential dependence on the
underlying cardiac pathology. Currently, it is accepted that
plasmatic levels of apelin are increased in the early stages of
heart failure but decreased in later stages (7, 8, 14), a fact that
has been suggested to promote a transient compensatory re-
sponse.
So far, ACE2 is the only breakdown enzyme for apelin, and
therefore its activity, herein accessed by the formation of
ANG-(1–7) from ANG II, is increased likely as a compensa-
tory response to the increased plasmatic levels of apelin of the
MCT group. Furthermore, considering the well-known vaso-
dilator properties of apelin (20, 39) and ANG-(1–7) (13),
increased plasmatic levels of these agents could locally modify
the excessive production of vasoconstrictors, such as ANG II
and ET-1, and decrease RV pressure overload induced by
hypertrophied media of pulmonary vessels. Despite apelin
strong vasodilator effects, the mechanical afterload reduction is
not the only mechanism behind PH amelioration. As herein
demonstrated, apelin markedly attenuated the PH-induced neu-
rohumoral activation by preventing ANG II and ET-1 cardiac
overexpression and consequently their deleterious effects. This
results from a direct myocardial modulation of apelin since it
prevented ET-1 overexpression in the nonoverloaded LV.
Moreover, Zisman et al. (43) demonstrated that ANG-(1–7) is
produced in the intact human heart, is counterregulatory of
ANG II, and is decreased when ANG II formation is sup-
pressed by an ACE inhibitor, suggesting that a major pathway
for the formation of ANG-(1–7) was directly dependent on the
availability of ANG II as a substrate. Interestingly, although
ANG-(1–7) effects are to a large extent mediated by the Mas
receptor (33, 37), the mRNA expression of this receptor in the
RV does not seem to be related with the plasma levels of
ANG-(1–7).
Increased circulating levels and myocardial upregulation
of ET-1 have been widely reported in PH (28), with the
extent of such increase being directly proportional to the
severity of the disease (15). Elevated endogenous ET-1
production, acting through endothelin receptor ETA, causes
pulmonary vasoconstriction that is normally masked by
endogenous NO production and contributes to the progres-
sion of cardiopulmonary alterations in MCT-induced PH
(15, 28). In the present study, ET-1 mRNA levels were
increased in the overloaded RV and also in the nonover-
loaded LV of MCT animals and normalized in the MCT-AP
group. In fact, our laboratory has previously demonstrated
that MCT-treated rats with long-standing PH presents auto-
crine/paracrine system activation of the LV in the absence
of a direct hemodynamic stress, myocardial hypertrophy, or
fibrosis. In the present study, we confirmed this aspect and
additionally showed that Pyr-AP13 treatment of the MCT
rats directly modulates myocardial neurohumoral environ-
ment of the overloaded and nonoverloaded myocardium.
Regarding ANG II, several authors have reported ANG II
and ACE upregulation in the MCT-induced PH rat model
(26, 40). In APJ-deficient mice, Ishida and collaborators
(20) demonstrated the role of apelin-APJ system against the
vasopressor action of ANG II. Accordingly, the present
study showed a normalization of the increased ANG II
overexpression in the MCT-AP group. This strongly sug-
gests that apelin is a new neurohumoral modulator, acting as
a counterregulatory peptide for ET-1 and ANG II vasocon-
strictor properties. Moreover, the significant reduction of
BNP mRNA expression in MCT-AP animals certainly con-
firms the effectiveness of Pyr-AP13 chronic treatment in
decreasing RV pressure overload and ameliorating the myo-
cardial injuries induced by PH.
Although further work is required to delineate the pathways
by which exogenous apelin modulates PH-induced neurohu-
moral activation as well as its myocardial production, we have
demonstrated that RV and pulmonary deleterious effects of
MCT-induced PH are accompanied by abnormalities of the
apelin-APJ system. The proposed mechanism suggests that in
the course of PH the decreased expression of the apelinergic
system in the myocardium triggers a compensatory increase of
plasmatic apelin, raising ACE2 activity and consequently
ANG-(1–7) formation. Both vasodilator species might help to
reduce PH-induced RV pressure overload. Chronic Pyr-AP13
administration started early in the course of PH was able to
1) upregulate apelin myocardial expression and prevent a
concomitant increase of its plasmatic levels, 2) prevent apelin
and APJ mRNA downregulation and ensure a normal vasodi-
lator effect of apelin-APJ system, and 3) blunt ET-1 and ANG
II upregulation showing its modulator role in myocardial neu-
rohumoral activation. Altogether these effects show that Pyr-
AP13 treatment decreases RV overload and hypertrophy, im-
proves biventricular diastolic function, and so ameliorates PH.
These findings suggest a possible role of the apelin-APJ system
in the pathophysiology of PH, as well as its use as a potential
therapeutic target in this disease.
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